Rebastinib - Deciphera Pharmaceuticals

Drug Profile

Rebastinib - Deciphera Pharmaceuticals

Alternative Names: DCC-2036; DP-1919; DP-1919.TO

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Albert Einstein College of Medicine; Deciphera Pharmaceuticals
  • Class Antineoplastics; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors; Proto-oncogene protein c-hck inhibitors; TIE 2 receptor antagonists; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Phase I Breast cancer

Most Recent Events

  • 24 Oct 2018 Deciphera Pharmaceuticals plans a phase I/II trial for Solid tumour (Late-stage disease) in USA (NCT03717415)
  • 26 Sep 2018 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03601897)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top